Royalty Pharma PLC $RPRX Shares Sold by Koss Olinger Consulting LLC

Koss Olinger Consulting LLC lowered its stake in Royalty Pharma PLC (NASDAQ:RPRX) by 1.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,403 shares of the biopharmaceutical company’s stock after selling 353 shares during the quarter. Koss Olinger Consulting LLC’s holdings in Royalty Pharma were worth $1,131,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Victory Capital Management Inc. grew its stake in shares of Royalty Pharma by 270.4% in the first quarter. Victory Capital Management Inc. now owns 3,623,134 shares of the biopharmaceutical company’s stock valued at $112,788,000 after buying an additional 2,644,923 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Royalty Pharma by 8.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,847,934 shares of the biopharmaceutical company’s stock valued at $88,656,000 after purchasing an additional 226,048 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Royalty Pharma by 37.0% in the first quarter. AQR Capital Management LLC now owns 2,608,090 shares of the biopharmaceutical company’s stock valued at $80,381,000 after purchasing an additional 704,414 shares during the last quarter. Invesco Ltd. boosted its holdings in Royalty Pharma by 34.1% in the first quarter. Invesco Ltd. now owns 1,284,418 shares of the biopharmaceutical company’s stock valued at $39,984,000 after purchasing an additional 326,525 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its holdings in Royalty Pharma by 7.5% in the first quarter. Alliancebernstein L.P. now owns 1,241,051 shares of the biopharmaceutical company’s stock valued at $38,634,000 after purchasing an additional 86,873 shares during the last quarter. Institutional investors and hedge funds own 54.35% of the company’s stock.

Royalty Pharma Trading Up 1.1%

NASDAQ:RPRX opened at $37.26 on Monday. The company has a quick ratio of 1.26, a current ratio of 1.26 and a debt-to-equity ratio of 0.74. The business’s 50 day moving average is $36.12 and its two-hundred day moving average is $35.04. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $38.00. The company has a market cap of $21.73 billion, a PE ratio of 21.54, a P/E/G ratio of 2.05 and a beta of 0.60.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.04. Royalty Pharma had a return on equity of 25.54% and a net margin of 44.23%.The company had revenue of $578.67 million for the quarter, compared to the consensus estimate of $750.06 million. On average, analysts predict that Royalty Pharma PLC will post 4.49 EPS for the current year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be issued a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Friday, November 14th. Royalty Pharma’s dividend payout ratio (DPR) is currently 50.87%.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Wall Street Zen downgraded Royalty Pharma from a “buy” rating to a “hold” rating in a report on Saturday, September 13th. Citigroup increased their price target on Royalty Pharma from $40.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, July 22nd. Weiss Ratings downgraded Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday. Morgan Stanley reduced their price target on Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Finally, The Goldman Sachs Group assumed coverage on Royalty Pharma in a report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $46.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.